CLLS and ALCLS Related Headlines
Go Back- Allogene retains control of cancer therapy after arbitration ruling
- Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
- Cellectis Announces Arbitral Decision in Dispute with Servier
- Moligo Technologies and Cellectis Demonstrate Potential of Enzymatic Single-Stranded DNA for Non-Viral Gene Editing in Nature Communications
- Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells
- Cellectis reports Phase 1 data for leukemia therapy lasme-cel
- Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL
- Cibus and AgVayā Collaborate to Introduce Indian Rice Growers to New Solutions to Scale Crop Productivity Through Advanced Gene Editing
- Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers
- Cellectis Reports Second Quarter 2025 Financial Results & Business Updates
- The U.S. Food and Drug Administration Completes Review of Cibus’ Altered Lignin Alfalfa Developed in Partnership with S&W Seed Company for use in Livestock Feed
- Cibus, Inc. Announces Closing of $27.5 Million Public Offering
- USDA Designates Cibus’ Herbicide Tolerance Canola Trait HT2 as Not Regulated Under USDA’s Biotechnology Regulations
CLLS and ALCLS Related Press Releases
Go Back- Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
- Cellectis Announces Arbitral Decision in Dispute with Servier
- Moligo Technologies and Cellectis Demonstrate Potential of Enzymatic Single-Stranded DNA for Non-Viral Gene Editing in Nature Communications
- Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells
- Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL
- Cibus and AgVayā Collaborate to Introduce Indian Rice Growers to New Solutions to Scale Crop Productivity Through Advanced Gene Editing
- Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers
- Cellectis Reports Second Quarter 2025 Financial Results & Business Updates
- The U.S. Food and Drug Administration Completes Review of Cibus’ Altered Lignin Alfalfa Developed in Partnership with S&W Seed Company for use in Livestock Feed
- Cibus, Inc. Announces Closing of $27.5 Million Public Offering
- USDA Designates Cibus’ Herbicide Tolerance Canola Trait HT2 as Not Regulated Under USDA’s Biotechnology Regulations
CLLS and ALCLS Related SEC Filings
Go Back- Form 6-K Cellectis S.A. For: Jan 08
- Form 6-K Cellectis S.A. For: Dec 15
- Form SCHEDULE 13D/A Cellectis S.A. Filed by: Bpifrance Participations SA
- Form 6-K Cellectis S.A. For: Dec 08
- Form 6-K Cellectis S.A. For: Dec 05
- Form 6-K Cellectis S.A. For: Nov 19
- Form 6-K Cellectis S.A. For: Nov 07
- Form 6-K Cellectis S.A. For: Nov 03
- Form 6-K Cellectis S.A. For: Oct 29
- Form 6-K Cellectis S.A. For: Oct 16
- Form 6-K Cellectis S.A. For: Oct 16
- Form 6-K/A Cellectis S.A. For: Jun 30
- Form 6-K Cellectis S.A. For: Oct 07
- Form S-8 Cellectis S.A.
- Form 6-K Cellectis S.A. For: Aug 04
- Form 6-K Cellectis S.A. For: Aug 04
- Form 6-K Cellectis S.A. For: Jul 28
- Form EFFECT Cellectis S.A.
- Form F-3 Cellectis S.A.
- Form 6-K Cellectis S.A. For: Jun 26
- Form 6-K Cellectis S.A. For: Jun 26
